JFGIW
ARQT icon

Johnson Financial Group Inc (Wisconsin)’s Arcutis Biotherapeutics ARQT Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-199
Closed -$2.63K – 859
2024
Q4 		$2.63K Sell
199
-56
-22% -$614 ﹤0.01% 789
2024
Q3 		$2.37K Buy
+255
New +$2.52K ﹤0.01% 852

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s ARQT Position: Q1 2025 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Arcutis Biotherapeutics (ARQT) in Q1 2025, closing a stake of 199 shares — an estimated $2.63K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in ARQT in Q3 2024 and held it in 2 quarters. The position peaked at $2.63K in Q4 2024. 241 funds tracked by Wall St. Rank hold ARQT as of Q1 2025.

  • Johnson Financial Group Inc (Wisconsin) reported no remaining Arcutis Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Johnson Financial Group Inc (Wisconsin) sold 199 Arcutis Biotherapeutics shares in Q1 2025, an estimated $2.63K.
  • Johnson Financial Group Inc (Wisconsin) first reported a position in Arcutis Biotherapeutics in Q3 2024 and held it in 2 quarters.
  • Johnson Financial Group Inc (Wisconsin)'s Arcutis Biotherapeutics position peaked at $2.63K in Q4 2024.
  • 241 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2025.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2025, filed 15 May 2025.